Compositions for producing glucose syrups

US10337041B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10337041-B2
Application numberUS-201515116006-A
CountryUS
Kind codeB2
Filing dateFeb 6, 2015
Priority dateFeb 7, 2014
Publication dateJul 2, 2019
Grant dateJul 2, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to a method of making glucose syrup from liquefied starch comprising, (a) contacting the liquefied starch with a glucoamylase, a pullulanase, and optionally an alpha-amylase wherein the ratio of pullulanase dose expressed as NPUN/gDS, to alpha-amylase dose expressed as FAU(A)/gDS is at least 60, particularly at least 75, particularly at least 100, more particularly at least 150, more particularly at least 200, more particularly at least 250, more particularly at least 300, more particularly at least 400, more particularly at least 500, more particularly at least 600, more particularly at least 800 or if no alpha-amylase is present the pullulanse is present in a dose of at least 0.5, particularly at least 0.75, particularly at least 1.0, particularly at least 1.5 NPUN/gDS, and (b) saccharifying the liquefied starch.

First claim

Opening claim text (preview).

The invention claimed is: 1. A composition comprising an alpha-amylase, a pullulanase and a glucoamylase, wherein the alpha-amylase has at least 90% sequence identity to SEQ ID NO: 5 or a mature polypeptide thereof, the pullulanase has at least 90% sequence identity to SEQ ID NO: 16 or a mature polypeptide thereof, the glucoamylase has at least 90% sequence identity to SEQ ID NO: 4 or a mature polypeptide thereof, and the ratio of pullulanase dose in New Pullulanase Units Novozymes (NPUN)/gDS to alpha-amylase dose in Acid Fungal Alpha-amylase Units (FAU(A))/gDS is at least 60 and the ratio of pullulanase dose in New Pullulanase Units Novozymes (NPUN)/gDS to glucoamylase dose in Glucoamylase Units (AGU)/gDS is in the range of 2-15. 2. The composition of claim 1 , wherein the ratio of pullulanase dose in NPUN/gDS to alpha-amylase dose in FAU(A)/gDS is in the range of 100-700. 3. The composition of claim 1 , wherein the ratio of pullulanase dose in NPUN/gDS to alpha-amylase dose in FAU(A)/gDS is in the range of 200-600. 4. The composition of claim 1 , wherein the ratio of pullulanase dose in NPUN/gDS to alpha-amylase dose in FAU(A)/gDS is in the range of 300-500. 5. The composition of claim 1 , wherein the ratio of pullulanase dose in NPUN/gDS to alpha-amylase dose in FAU(A)/gDS is in the range of 350-500. 6. The composition of claim 1 , wherein the ratio of pullulanase dose in NPUN/gDS to alpha-amylase dose in FAU(A)/gDS is in the range of 375-475. 7. The composition of claim 1 , wherein the ratio of pullulanase dose in NPUN/gDS to alpha-amylase dose in FAU(A)/gDS is in the range of 400-450. 8. The composition of claim 1 , wherein the ratio of pullulanase dose in NPUN/gDS to glucoamylase dose in AGU/gDS is in the range of 2-10. 9. The composition of claim 1 , wherein the ratio of pullulanase dose in NPUN/gDS to glucoamylase dose in AGU/gDS is in the range of 2-5. 10. The composition of claim 1 , wherein the ratio of pullulanase dose in NPUN/gDS to glucoamylase dose in AGU/gDS is in the range of 3-5. 11. The composition of claim 1 , wherein the ratio of pullulanase dose in NPUN/gDS to glucoamylase dose in AGU/gDS is in the range of 3.5-4. 12. The composition of claim 1 , wherein the composition comprises an alpha-amylase of SEQ ID NO: 5, a pullulanase of SEQ ID NO: 16 and a glucoamylase of SEQ ID NO: 4. 13. A method of making glucose syrup, comprising contacting liquefied starch with a composition of claim 1 . 14. The method of claim 13 , wherein the initial dry solids content (DS) in the liquefied starch is at least 25%. 15. The method of claim 13 , wherein contacting time is at least 24 hours.

Assignees

Inventors

Classifications

  • obtained by saccharification of starch or raw materials containing starch · CPC title

  • Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches · CPC title

  • Monosaccharides (2-ketogulonic acid C12P7/60) · CPC title

  • Pullulanase (3.2.1.41) · CPC title

  • Alpha-amylase (3.2.1.1) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10337041B2 cover?
The present invention relates to a method of making glucose syrup from liquefied starch comprising, (a) contacting the liquefied starch with a glucoamylase, a pullulanase, and optionally an alpha-amylase wherein the ratio of pullulanase dose expressed as NPUN/gDS, to alpha-amylase dose expressed as FAU(A)/gDS is at least 60, particularly at least 75, particularly at least 100, more particularly…
Who is the assignee on this patent?
Novozymes As
What technology area does this patent fall under?
Primary CPC classification C12P19/14. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).